TLC Session 3 (Gerd Geerling): Perspective Study - Real-World Evidence of Ikervis® effectiveness, tolerability and safety
Date: 5/08/2023 (AEST)
Venue: 410 Sandy Bay Road, Sandy Bay, TAS, 7005
Provider: Optometry Tas
Contact: Jonathan Jones, [E] firstname.lastname@example.org, [P] (03) 6224 3360
- Understand how to escalate treatment in patients with dry eye disease with severe keratitis with ciclosporin eye drops.
- Gain insight into the relevance of real-world evidence to help guide the practical management of patients with ciclosporin eye drops, specifically Ciclosporin 0.1% eye drops.
- Know the pathways for applying for PBS Authority application for Ikervis (ciclosporin 0.1% eye drops), where eligible.
Max CPD hours awarded: 1.75
|Perspective Study: Real-World Evidence of Ikervis® effectiveness, tolerability and safety|
|Duration of CPD Session/Module|
|Duration of CPD Session/Module inclusive of Assessment Component|